Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces Year-End 2018 Financial Results
- Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019 - The RENEW Adaptive Phase 3 Clinical Trial in Dry Eye Disease Expected to Begin in First Half of 2019 - Results from the SOLACE Phase 3 Clinical Trial in Noninfectious Anterior Uveitis Expected in
View HTML
Toggle Summary Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019
LEXINGTON, Mass. , March 1, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Friday,
View HTML
Toggle Summary Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day
Phase 3 Results from ALLEVIATE Trial in Allergic Conjunctivitis Expected in Early 2019 Co-Primary Endpoints Confirmed for Phase 3 Clinical Trial in Dry Eye Disease, Expected to Begin in First Half of 2019 Phase 3 Clinical Trial of ADX-2191 in Proliferative Vitreoretinopathy Expected to Begin in
View HTML
Toggle Summary Aldeyra Therapeutics to Host 2019 Research & Development Day
LEXINGTON, Mass. , Feb. 12, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a
View HTML
Toggle Summary Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Addition of Phase 3-Ready Clinical Program Orphan Drug Designation for Proliferative Vitreoretinopathy, A Potentially Blinding Disease with No Approved Treatment Initial Clinical Trial Results Expected in 2020 LEXINGTON, Mass. , Jan. 29, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc.
View HTML
Toggle Summary Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations
LEXINGTON, Mass. , Jan. 15, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to inventing, developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Stephen
View HTML
Toggle Summary Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer
LEXINGTON, Mass. , Jan. 3, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin has been promoted to
View HTML
Toggle Summary Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial
LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the last patient has completed
View HTML
Toggle Summary Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference
LEXINGTON, Mass. , Nov. 28, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C.
View HTML
Toggle Summary Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results
Reported Positive Data from Phase 2b Clinical Trial of Topical Ocular Reproxalap in Dry Eye Disease Announced Positive Top-Line Data from Investigator-Sponsored Phase 1/2 Clinical Trial of ADX-1612 in Malignant Mesothelioma Raised $67.6 Million, Operations Expected to be Funded Through 2020
View HTML